Syntara Limited has released a press release.
LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Syntara
- Pharmaxis Releases Positive Results of Phase 1 Clinical Tria
- Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
- FDA Factory Approval and Relaunch of Aridol in US Market
- Capital Raising Presentation
- Trading Halt Announcement - System Upgrade
Later from Syntara
- Pharmaxis AGM - CEO Presentation
- Pharmaxis Announces First Relaunch Sales of Aridol in USA
- Pharmaxis announces resubmission of bronchitol nda in usa
- Pharmaxis Announces LOXL2 Program Phase 2 Ready
- Quarterly Shareholder Update - December 2018
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara